A series of novel angiotensin II receptor 1 antagonists (1a-f, 2a-f) were designed, synthesized and evaluated. Radioligand binding assays showed that all these prepared compounds displayed nanomolar affinity for angiotensin II type 1 receptor, among which compound 1f was more affinitive than telmisartan at the same order of magnitude with an IC 50 value of 1.13 AE 1.68 nM. The antihypertensive effects showed that all these compounds could decrease blood pressure in a dose dependent manner on spontaneously hypertensive rats. And compound 2-(4-( (2- 4.24 h respectively. Compound 1f was distributed into tissues rapidly and extensively after oral administration and the level of it was the highest in the liver, followed by in the kidney, and the lowest in brain. The acute toxicity assays in ICR rats of 1f showed that it had low acute toxicity with an LD 50 value of 1459.89 mg kg
Introduction
Hypertension is a growing undesired symptom and usually associated with many complications, such as coronary heart disease, stroke, myocardial infarction and renal disease. The renin-angiotensin aldosterone system (RAAS) plays a critical role in blood pressure regulation and electrolyte/uid homeostasis.
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The octapeptide angiotensin II is the main pressor component of the RAAS and angiotensin II (Ang II) receptor antagonists are widely accepted as novel antihypertensive drugs because of the small side effects and good therapeutic proles. 2 The rst nonpeptidic Ang II receptor antagonists, N-benzylimidazole-5-acetic acid derivatives, were rstly reported by the Takeda laboratories.
Since then, this imidazole lead has been developed into a series of potent, selective and orally active AT 1 receptor antagonists. Losartan ( Fig. 1) is the most widely used drug of this series, and numerous modications to its chemical structure have generated a large number of Ang II antagonists including valsartan, irbesartan, telmisartan, candesartan, olmesartan and so on.
3,4 All these drugs contain common structural features represented by In our previous work, a potential new compound 2-[4-[[2-npropyl-4-methyl-6-(1-methylbenzimidazol-2-yl)benzimidazole-1-yl]methyl]-1H-indol-1-yl]benzoicacid (BBIB, Fig. 1 ) was found reducing blood pressure more effectively than losartan and telmisartan. 10 Based on the analysis of the chemical structure of telmisartan and BBIB, herein, a series of novel potent non-peptide AT 1 receptor antagonists were designed and synthesized. Their pharmacological activities were evaluated, including the affinity to AT 1 receptor in vitro and antihypertensive effect in vivo. The plasma pharmacokinetics, tissue distribution in Wistar rats and acute toxicity in ICRs of the most potential compound were further investigated. . Data were average values of 6 experiments (mean AE SD). *, **Significant difference from the control, p < 0.05 and p < 0.01, respectively.
Results and discussion

Chemistry
We developed a general and useful synthesis of indole derivatives 1a-f, 2a-f with a variety of substituents. In short, this procedure comprised of two coupling parts, one gave the chlorine and the other gave the heterocyclic amine. We initially synthesized the halide component which was coupled to the heterocyclic fragment to construct the target molecule. And the preparation of new compounds was performed by means of a multistep procedure described in Scheme 1 and 2.
The synthesis of 8a, 5a-f and 1a-f were outlined in Scheme 1. 4-Chlorinemtehyl-N-phenyl indole compound (8a) was obtained by chlorinating the ester of ethyl benzoate compound (7a) which was achieved through esterication of benzoic acid compound (6a). 6-Substituted benzimidazole compounds (5a-f) were obtained by the condensation reaction of 6-benzimidazole carboxylic acid compounds (3a-c) with different ortho amino phenol compounds (4a-b). They were reacted with 8a to get the designed carboxylic acid compounds (1a-f).
The synthesis of 5-chlorinemethyl-N-phenyl indole compound (8b) was similar to that of 8a which was outlined in Scheme 2. Compound 8b reacted with 5a-f to get the designed carboxylic acid compounds (2a-f).
Biological evaluation
Affinities to Ang II (AT 1 ) receptor in vitro. The affinity of the prepared compounds and losartan for the AT 1 Table 2 and the mean peak plasma concentration-time curve was shown in Fig. 4 . The maximum concentration (C max ) value was 17.92 AE 10.85 ng mL À1 , the area under the concentration-time curve from 0 to 72 h (AUC 0-72 ) was 252.85 AE 144.59 ng mL À1 h, the elimination half-lives (T 1/2 ) was 17.16 AE 4.24 h and the time reach to maximum concentration was 2 h. The compound levels in heart, liver, spleen, kidney and brain of Wistar rats at 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 h post oral administration of compound 1f at 10 mg kg À1 were shown in Fig. 5 and the pharmacokinetic parameters were shown in Table 3 . It was found that 1f was distributed extensively in rat tissues. And it was accumulated especially in liver which exhibited the highest concentration of 152.87 AE 10.10 ng g
À1
followed by kidney of 5.84 AE 2.14 ng g À1 and the lowest in brain of 1.31 AE 0.59 ng g À1 . These results indicate that liver and renal transporters might play an important role in the disposition of 1f. Since the highest concentration of telmisartan aer oral administration was also detected in liver and followed by in kidney, 11 the distribution of 1f appeared to have some similarity to telmisartan. Information on the likelihood of crossing the blood brain barrier (BBB) is important for targets related to central nervous system (CNS). 1f was detectable in brain which Table 2 Pharmacokinetic parameters of compound 1f in plasma of male Wistar rats after oral administration at 10 mg kg
. Data were average values of 8 experiments (mean AE SD) means it could penetrate the BBB. Telmisartan was also able to cross the BBB aer oral administration, but other sartans such as candesartan, losartan, and valsartan were poorly penetrated to BBB.
12 Thus, 1f may have effect on dilating cerebral blood vessels, improving cerebral circulation and hence could be useful for the potential treatment of ischemic cerebrovascular disease.
13,14
These results also showed that compound 1f was absorbed and distributed efficiently and metabolized gradually in plasma and in tissues of Wistar rats.
Acute toxicity test. The acute toxicity assay showed that compound 1f had low acute toxicity with the LD 50 Table 3 Pharmacokinetic parameters of compound 1f in tissues of Wistar rats after oral administration at 10 mg kg
À1
. Data were average values of 6 experiments (mean AE SD) respectively. It was well distributed in tissues including in brain which suggested that 1f could cross the blood-brain barrier (BBB) and might play important role in the control of central nervous system blood pressure. The acute toxicity assay of 1f showed that it had low acute toxicity with no signicant changes in the weight and no obvious untoward reactions. The LD 50 value of it was 1459.89 mg kg À1 . These encouraging results make 1f an effective and durable anti-hypertension drug candidate deserving for further investigation.
Material and methods
Chemistry
All chemical reagents were purchased from commercial suppliers and were used without further purication. Yields of the puried products were not optimized. Melting points (MP) were measured on an electro thermal melting point apparatus and were not corrected. 1 H NMR spectra were measured on a Bruker 400 MHz spectrometer using TMS (Me 4 Si) as internal standard. ESI-MS spectra were recorded on a Micromass triple quadrupole mass spectrometer. Column chromatography was performed using silica gel H (300-400 meshes).
General procedure for the synthesis of 3a-c. Methyl 4-amino-3-methylbenzoate (10.00 g, 60.58 mmol) was acylated with alkyl acyl chloride (90.87 mmol) and triethylamine (16.79 mL, 121.16 mmol) in DCM at 0 C. The resulting amide was reacted with fuming nitric acid in sulfuric acid (60%) at À20 C. The resulting nitro-compound was reduced with hydrogen (5 bar) and RANEY® Ni (0.79 g, 13.34 mmol) in methanol at reux. The resulting amino compound was dissolved in glacial acetic acid and heated under reux for 1 h. Aer evaporation of the acetic acid, water was added to the residue and the pH value was adjusted to 9 by addition of concentrated ammonia. This solution was extracted with ethyl acetate (3 Â 100 mL). The combined organic layers were washed with aqueous NaHCO 3 solution and dried over MgSO 4 . Aer ltration, the solvent was removed under reduced pressure.
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Methyl 2-ethyl-4-methyl-benzo[d]imidazole-6-carboxylate (3a). The above general procedure was followed by using propionyl chloride. The residue was puried by column chromatography to give the product as yellow oil. Yield: 50%. 1 2-Butyl-4-methyl-6-(oxazolo [4,5-b] pyridine-2-yl)benzimidazole (5f). The synthesis of compound 5f was similar to that of compound 5a, obtaining as yellow solid. Yield: 51%. C. General procedure for the synthesis of 8a-b. The solution of compound 7a/7b (500 mg, 1.78 mmol) in anhydrous dichloromethane (100 mL) was stirred in ice bath and slowly added hydrogen chloride ethanol (0.5 mL, about 35%) solution. The solution was allowed to stir at room temperature for 1-2 h. The reaction mixture was washed with water (50 mL Â 3), saturated brine (50 mL Â 3) and dried over anhydrous MgSO 4 . Aer ltration, the solvent was removed under reduced pressure.
Methyl 2-(5-(chloromethyl)-1H-indol-1-yl)benzoate (8a). The above general procedure get brown solid or brown oil compound (8a). Yield: 82%. 
Methyl 2-(5-(chloromethyl)-1H-indol-1-yl)benzoate (8b).
The synthesis of compound 8b was similar to that of compound 8a, obtaining brown yellow oil product. Yield: 82%. 1 General procedure for the synthesis of 1a-f, 2a-f. Compound 5 (1.20 mmol) was dissolved in DMF (20 mL), and then sodium hydride (86.4 mg, 3.6 mmol) was added. The solution was stirred at room temperature for 30 min, followed by addition the solution of compound 8a/8b (395 mg, 1.32 mmol) in DMF (10 mL) slowly, and the reaction mixture was continued to stirring at room temperature for about 2-4 h. Sodium hydroxide aqueous (2 M, 2 mL) was added and stirred at room temperature for another 2-4 h. The reaction mixture was adjusted the pH to 5-6 by 2 M hydrochloric acid, then dichloromethane (50 mL) and water (100 mL) was added into the mixture, and the organic phase was collected. The aqueous phase was extracted with dichloromethane (50 mL Â 3) and then combined the organic phase. The combined organic phase was washed with saturated brine (100 mL Â 4), dried over anhydrous MgSO 4 and ltrated. The ltrate was removed under reduced pressure. . Blood samples were collected from each rat by retro-orbital puncture at a predetermined time interval of pre-dose, 0. 5, 1, 2, 4, 6, 8, 12 , 24, 48 and 72 h into the polypropylene microfuge tubes containing heparin. Plasma was separated by centrifuging the blood samples at 4000 Â g at 4 C for 10 min. 200 mL plasma samples were collected and followed by 100 mL of internal standard. Acetonitrile (200 mL) was added to precipitate proteins and the sample was vortexed for 1 min. Precipitated proteins were separated by centrifugation for 5 min at 12 000 Â g at 4 C. . The calibration line was generated by least squares linear regression of the peak height ratio (PHR) of analyte/internal standard against nominal concentration with a weighting of concentration À2 .
2-(4-((2-Ethyl-4-methyl-6-(benzoxazol-2-yl)benzimidazole-1-yl) methyl)-1H-indol-1-yl)benzoic acid (1a
(m, 2H), 1.00 (t, J ¼ 7.3 Hz, 3H). 13 C NMR (101 MHz, DMSO): d ppm 167.8, 163.9, 157.9, 150.6, 145.1, 142.2, 137.6, 136.5
18,19
66 male Wistar rats (180-200 g, Shanghai Slac Laboratory Animal Company, Shanghai, China) were used to investigate the tissue distribution of compound 1f. Animals were orally administrated with 1f at 10 mg kg À1 . Heart, liver, spleen, lung, kidney and brain samples were collected at 0 (prior to dosing), 0.5, 1, 2, 4, 6, 8, 12, 24, 48 and 72 h post-dosing (n ¼ 6). 0.25 g samples from different tissues were obtained aer being rinsed with normal saline solution and blotted with lter paper. The samples were grinded into tissue uid (0.25 g/1 mL normal saline solution) with High-speed Homogenizer (PRO200, Biogen series, USA). The tissue uid was added with 4 mL methanol and vortexed for 1 min and then centrifuged at 10 000 Â g for 10 min. 2 mL supernatant was obtained and dried in gentle stream of nitrogen ow at 50 C. The residue was spun for 2 min aer being reconstituted with 100 mL methanol, and was centrifuged at 12 000 Â g for 5 min to get supernatant sample. 20 mL supernatant samples were taken to analyze through LC-MS.
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Acute toxicity test. To detect the safety of compound 1f, the acute toxicity assay was carried out with 50 normal ICRs (18-20 g, Academia Sinica, China). The LD 50 value was delivered via intragastric administration (ig) at doses of 3331.94, 2332.36, 1632.65, 1142.86, 800.00 mg kg À1 . The lethal dose (LD 50 ) and 95% condence limits were determined by logistic regression analysis (GLM) curve tting of the 14 days' mortality data. Survivals were observed continuously and recorded systematically for physiological toxicity including weight, mobility, aggressiveness and respiratory movements. At the 15th day, the survivals were dissected to examine the pathological changes of organs.
20
Statistics. Results were expressed as means AE SD. Data were analyzed by one-way analysis of variance. When overall statistical signicance was achieved (P < 0.05), anova one way and t-test statistical were used to compare each of the doses to the vehicle control. Probability values less than 0.05 were considered to be signicant. Binding isotherms from competition studies were obtained using the nonlinear regression program GraphPad Prism 5 soware (Network of Science So-ware of China) and pharmacokinetic parameters were acquired by DAS.2.0 soware. Animals were maintained in accordance with the guidelines issued by the Institutional Animal Care and Use Committee of China, and approved by the institutional ethical committee of Donghua University.
